Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Denali Therapeutics (NASDAQ:DNLI) had its price objective lifted by Robert W. Baird from $29.00 to $32.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s target price would suggest a potential upside of 76.21% from the company’s previous close.

Other analysts also recently issued reports about the company. Jefferies Financial Group reissued a “buy” rating and issued a $40.00 target price on shares of Denali Therapeutics in a report on Monday, March 2nd. UBS Group initiated coverage on Denali Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating on the stock. Wolfe Research began coverage on Denali Therapeutics in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. BTIG Research boosted their price objective on Denali Therapeutics from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Morgan Stanley reissued an “overweight” rating and issued a $40.00 price objective on shares of Denali Therapeutics in a report on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.82.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $18.16 on Thursday. The company’s fifty day moving average price is $20.43 and its 200 day moving average price is $17.83. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $23.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The firm has a market capitalization of $2.88 billion, a P/E ratio of -6.11 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same quarter last year, the company posted ($0.67) earnings per share. As a group, sell-side analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. This represents a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Ryan J. Watts sold 35,198 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. The trade was a 10.60% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Denali Therapeutics by 8.9% during the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after buying an additional 1,064,972 shares in the last quarter. Baillie Gifford & Co. boosted its stake in shares of Denali Therapeutics by 6.2% in the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after buying an additional 719,304 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Denali Therapeutics by 28.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after buying an additional 1,615,565 shares in the last quarter. Temasek Holdings Private Ltd grew its holdings in Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after acquiring an additional 1,657,142 shares during the period. Finally, State Street Corp raised its position in Denali Therapeutics by 14.6% in the fourth quarter. State Street Corp now owns 6,263,371 shares of the company’s stock worth $103,408,000 after acquiring an additional 799,110 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.